HUMA Insider Trading
Insider Ownership Percentage: 11.20%
Insider Buying (Last 12 Months): $507,525.42
Insider Selling (Last 12 Months): $25,940,916.90
Humacyte Share Price & Price History
Current Price: $1.44
Price Change: ▼ Price Decrease of -0.025 (-1.71%)
As of 04/29/2025 12:54 PM ET
Humacyte Insider Trading History
Humacyte Institutional Trading History
Data available starting January 2016
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
Read More on Humacyte
Volume
439,928 shs
Average Volume
3,570,986 shs
Market Capitalization
$222.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
Who are the company insiders with the largest holdings of Humacyte?
Humacyte's top insider investors include:
- Laura E Niklason (CEO)
- Brady W Dougan (Director)
- Gordon M Binder (Director)
- Kathleen Sebelius (Director)
- Heather Ledbetter Prichard (COO)
- Dale A Sander (CFO)
- William John Scheessele (Insider)
- Michael T Constantino (Director)
- Shamik J Parikh (Insider)
Learn More about top insider investors at Humacyte.
Who are the major institutional investors of Humacyte?
Which major investors are selling Humacyte stock?
In the last quarter, HUMA stock was sold by these institutional investors:
- Wealth Effects LLC
Within the last year, company insiders that have sold Humacyte company stock include:
- Laura E Niklason (CEO)
- Brady W Dougan (Director)
- Gordon M Binder (Director)
- Kathleen Sebelius (Director)
- Heather Ledbetter Prichard (COO)
Learn More investors selling Humacyte stock.
Which major investors are buying Humacyte stock?
In the previous quarter, HUMA stock was purchased by institutional investors including:
- Hamilton Lane Advisors LLC
- Columbia Advisory Partners LLC
In the last year, these company insiders have bought Humacyte stock:
- Laura E Niklason (CEO)
- Brady W Dougan (Director)
- Gordon M Binder (Director)
- Kathleen Sebelius (Director)
- Heather Ledbetter Prichard (COO)
- Dale A Sander (CFO)
- William John Scheessele (Insider)
- Michael T Constantino (Director)
Learn More investors buying Humacyte stock.